| Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching. | |
| | |
MedLine Citation:
|
PMID: 20216221 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Generic formulations of medications are marketed as therapeutically equivalent and less expensive than branded ones. Multiple studies and case reports have described relapses and worsening clinical outcome in patients after a switch from a brand name to a generic medication. Recent studies have shown that generics do not always lead to the expected costs savings, reducing the impetus to proceed with compulsory generic switching. We report on three patients who experienced clinical deterioration after commencing the generic formulation of their previous brand name psychotropic medication. We discuss key clinical differences between original and generic formulations of the same medication. The use of bioequivalence as an indicator of therapeutic and clinical equivalence, the lack of appropriate studies comparing generic and brand name medications and differences in excipients are some of the factors that could explain variation in clinical response between generic and brand name medications. Generic switching should be decided on a case-by-case basis with disclosure of potential consequences to the patient. |
| | |
Authors:
|
Howard C Margolese; Ya?l Wolf; Julie Eve Desmarais; Linda Beauclair |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: International clinical psychopharmacology Volume: 25 ISSN: 1473-5857 ISO Abbreviation: Int Clin Psychopharmacol Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-13 Completed Date: 2010-07-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8609061 Medline TA: Int Clin Psychopharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 180-2 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, McGill University, Montreal, Quebec, Canada. psychopharm.unit@mcgill.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Drugs, Generic
/
therapeutic use* Female Fluoxetine / therapeutic use Humans Male Mianserin / analogs & derivatives, therapeutic use Middle Aged Recurrence / prevention & control Therapeutic Equivalency* Valproic Acid / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Drugs, Generic; 24219-97-4/Mianserin; 54910-89-3/Fluoxetine; 61337-67-5/mirtazapine; 99-66-1/Valproic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective co...
Next Document: Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarat...